Medication info
Dibalton Tablet 80 mg (Valsartan)

Dibalton Tablet 80 mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›80mg / 1 tablet
Manufacturer / importer
Shinpoong Pharmaceutical Co., Ltd.
Appearance
Light red round film-coated tablet
Packaging
30 tablets (10 tablets/PTP x 3), 100 tablets (10 tablets/PTP x 10)
Approval status
Active

MFDS item code 201107217 · Approved 2011.09.27 · Insurance code 648506630

Summary

Main use
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. In patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be co-administered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When co-administering a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. Over the following weeks, increase the dose according to the patient's tolerability, administering 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, co-administration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required if creatinine clearance is 10 mL/min or greater. However, because there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this medicine. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of dose escalation outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
Children and adolescents under 18 years of age: The safety and efficacy have not been established. Children and adolescents under 18 years of age: The safety and efficacy have not been established.

Ingredients

Manufacturer
Shinpoong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular failure
  • left ventricular systolic dysfunction
View approved original text

This medication is primarily used for essential hypertension and heart failure. It is particularly suitable for heart failure patients who are intolerant to ACE inhibitors. Additionally, it helps reduce the risk of mortality in patients with left ventricular dysfunction after myocardial infarction. This medication is effective in controlling blood pressure and improving heart function, thereby reducing the risk of cardiovascular disease. It is used to treat symptoms and prevent complications at appropriate dosages depending on the patient's condition.

How to take

Adult dose

1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. In patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be co-administered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When co-administering a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. Over the following weeks, increase the dose according to the patient's tolerability, administering 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, co-administration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required if creatinine clearance is 10 mL/min or greater. However, because there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this medicine. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of dose escalation outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

Children and adolescents under 18 years of age: The safety and efficacy have not been established. Children and adolescents under 18 years of age: The safety and efficacy have not been established.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters; therefore, it should be discontinued immediately upon confirmation of pregnancy. Those with allergies to this medication or its ingredients, pregnant women or those likely to become pregnant, breastfeeding women, individuals with severe liver or kidney disease, and those with a history of specific angioedema should not take this medication. Elderly patients, those with hyperkalemia, liver impairment, heart valve disease, cardiovascular disease, or those who are sodium- or fluid-depleted should use this medication cautiously, especially since blood pressure may drop suddenly at the start of treatment. Common side effects may include headache, dizziness, fatigue, cough, or diarrhea, while rare but serious adverse reactions could involve angioedema, hepatitis, renal failure, hypoglycemia, or rhabdomyolysis, thus it's crucial to consult a healthcare provider if any abnormal symptoms occur. As this medication lowers blood pressure, caution is advised when driving or operating machinery, as dizziness or drowsiness may occur. Additionally, taking potassium-sparing diuretics or potassium supplements may lead to dangerously elevated potassium levels, thus frequent blood tests to monitor potassium levels are recommended when used in combination. This medication may interact with other antihypertensives or certain NSAIDs, leading to decreased effectiveness or affecting kidney function, so other medications currently being taken should be disclosed to a healthcare provider. In cases of overdose, severe hypotension, decreased consciousness, or shock may occur; immediate emergency care is required, which may include vomiting induction or saline infusion. This medication is not recommended for use in children and adolescents as safety and efficacy have not been sufficiently established.

Side effects

headache

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent air and moisture ingress, and keep it in a cool place below 30 degrees Celsius. Proper storage helps maintain the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

Light red round film-coated tablet

Package unit

30 tablets (10 tablets/PTP x 3), 100 tablets (10 tablets/PTP x 10)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.